Nortem Biogroup (XPAR:MLBIO) Capex-to-Operating-Income : 0.00 (As of Dec. 2022)

View and export this data going back to 2023. Start your Free Trial

What is Nortem Biogroup Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Nortem Biogroup's Capital Expenditure for the six months ended in Dec. 2022 was €0.00 Mil. Its Operating Income for the six months ended in Dec. 2022 was €0.63 Mil.

Hence, Nortem Biogroup's Capex-to-Operating-Income for the six months ended in Dec. 2022 was 0.00.

Nortem Biogroup Capex-to-Operating-Income Historical Data

The historical data trend for Nortem Biogroup's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nortem Biogroup Capex-to-Operating-Income Chart

Nortem Biogroup Annual Data

Trend

Dec21

Dec22

Capex-to-Operating-Income

Nortem Biogroup Semi-Annual Data
	Dec21	Dec22
Capex-to-Operating-Income	-	-

Competitive Comparison of Nortem Biogroup's Capex-to-Operating-Income

For the Packaged Foods subindustry, Nortem Biogroup's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nortem Biogroup's Capex-to-Operating-Income Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Nortem Biogroup's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Nortem Biogroup's Capex-to-Operating-Income falls into.

Nortem Biogroup Capex-to-Operating-Income Calculation

Nortem Biogroup's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2022 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (0)	/	0.634
	=	0.00

Nortem Biogroup's Capex-to-Operating-Income for the quarter that ended in Dec. 2022 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (0)	/	0.634
	=	0.00

Nortem Biogroup (XPAR:MLBIO) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

Nortem Biogroup Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Nortem Biogroup's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Nortem Biogroup (XPAR:MLBIO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Nortem Biogroup (XPAR:MLBIO) » Definitions » Capex-to-Operating-Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

Calle Alexander Humboldt 12B, Polígono Industrial Salinas de Poniente, El Puerto de Santa María, Cadiz, ESP, 11500

Website

https://www.nortembiogroup.com

Nortem Chem SA is engaged in the research, development, innovation and industrialization in the field of biochemistry and biotechnology, as well as the production and sale of products based on biochemical and/or biotechnological processes. It emerged as a biotechnological company in the field of the food and chemical industry, with maximum environmental awareness, concentrating its research and product development efforts on the development of environmentally friendly alternatives from renewable sources and obtaining its own microorganisms (Aspergillus Niger and Yarrowia lipolytica) with outstanding capabilities from adaptation and selection processes, avoiding the use of genetic modification technologies.

Nortem Biogroup (XPAR:MLBIO) Headlines

No Headlines